Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

138 Applying Pharmacogenomics in Therapeutics
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., et al. (2004).
EGF receptor gene mutations are common in lung cancers from “never smokers” and
are associated with sensitivity of tumors to gefitinib and erlotinib. Proceedings of the
National Academy of Sciences of the United States of America 101, 13306–13311.
Pao, W., Miller, V.A., Politi, K.A., Riely, G.J., Somwar, R., Zakowski, M.F., Kris, M.G., and
Varmus, H. (2005). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib
is associated with a second mutation in the EGFR kinase domain. PLoS Medicine 2, e73.
Pedace, L., Majore, S., Megiorni, F., Binni, F., De Bernardo, C., Antigoni, I., Preziosi, N.,
Mazzilli, M.C., and Grammatico, P. (2008). Identification of a novel duplication in the
APC gene using multiple ligation probe amplification in a patient with familial adenomatous
polyposis. Cancer Genetics and Cytogenetics 182, 130–135.
Pegram, M.D., Lipton, A., Hayes, D.F., Weber, B.L., Baselga, J.M., Tripathy, D., Baly, D.,
et al. (1998). Phase II study of receptor-enhanced chemosensitivity using recombinant
humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with
HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
Journal of Clinical Oncology 16, 2659–2671.
Perera, M.A., Innocenti, F., and Ratain, M.J. (2008). Pharmacogenetic testing for uridine
diphosphate glucuronosyltransferase 1A1 polymorphisms: Are we there yet?
Pharmacotherapy 28, 755–768.
Perner, S., Wagner, P.L., Demichelis, F., Mehra, R., Lafargue, C.J., Moss, B.J., Arbogast, S.,
et al. (2008). EML4-ALK fusion lung cancer: A rare acquired event. Neoplasia 10,
298–302.
Petersen, G.M., Slack, J., and Nakamura, Y. (1991). Screening guidelines and premorbid
diagnosis of familial adenomatous polyposis using linkage. Gastroenterology 100,
1658–1664.
Pharoah, P.D., Guilford, P., Caldas, C., and International Gastric Cancer Linkage Consortium.
(2001). Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation
carriers from hereditary diffuse gastric cancer families. Gastroenterology 121,
1348–1353.
Qian, H., Gao, F., Wang, H., and Ma, F. (2014). The efficacy and safety of crizotinib in the
treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: A metaanalysis
of clinical trials. BMC Cancer 14, 683.
Rendic, S., and Di Carlo, F.J. (1997). Human cytochrome P450 enzymes: A status report
summarizing their reactions, substrates, inducers, and inhibitors. Drug Metabolism
Reviews 29, 413–580.
Rettie, A.E., Wienkers, L.C., Gonzalez, F.J., Trager, W.F., and Korzekwa, K.R. (1994).
Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.
Pharmacogenetics 4, 39–42.
Richards, C.S., Bale, S., Bellissimo, D.B., Das, S., Grody, W.W., Hegde, M.R., Lyon, E.,
Ward, B.E., and Molecular Subcommittee of the ACMG Laboratory Quality Assurance
Committee. (2008). ACMG recommendations for standards for interpretation and
reporting of sequence variations: Revisions 2007. Genetics in Medicine 10, 294–300.
Riely, G.J., Marks, J., and Pao, W. (2009). KRAS mutations in non-small cell lung cancer.
Proceedings of the American Thoracic Society 6, 201–205.
Robson, M.E., Storm, C.D., Weitzel, J., Wollins, D.S., Offit, K., and American Society of
Clinical Oncology. (2010). American Society of Clinical Oncology policy statement
update: Genetic and genomic testing for cancer susceptibility. Journal of Clinical
Oncology 28, 893–901.
Ross, D.D., Yang, W., Abruzzo, L.V., Dalton, W.S., Schneider, E., Lage, H., Dietel, M.,
Greenberger, L., Cole, S.P., and Doyle, L.A. (1999). Atypical multidrug resistance:
Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected
cell lines. Journal of the National Cancer Institute 91, 429–433.